Sinopharm-CICC
VC Fund
Shanghai, China
Sinopharm-CICC is a private equity fund focused on investments in the healthcare industry under CICC Capital.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Sinopharm-CICC invests in
Stages Sinopharm-CICC invests in
Countries Sinopharm-CICC invests in
Investment Focus
Industry
- Medical 5 (33%)
- Biotechnology 4 (27%)
- Health Care 3 (20%)
- Medical Device 3 (20%)
- Pharmaceutical 3 (20%)
Stage
- Series A 3 (20%)
- Venture - Series Unknown 3 (20%)
- Series B 2 (13%)
- Series C 2 (13%)
- Seed 1 (7%)
Country
- China 11 (73%)
- United States 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| DynaFlow focuses on scientific research services, with "serving scientific research with innovation" as its core philosophy. It is committed to providing clients with full lifecycle AI+dark laboratory solutions. Services cover the entire lifecycle of dark laboratories, including laboratory design (consulting, feasibility studies,preliminary design, construction drawings, BIM design, etc.) | Series B / Nov 20, 2025 | ||
|
Guangzhisuoji Medical Technology
|
Guangzhisuoji Medical is a high-tech enterprise focusing on the research and development of soft hydrophilic contact lenses. The company is committed to improving the comfort, safety and functionality of contact lenses through innovative technologies to meet the growing market demand. | Series A / Jul 16, 2025 | |
Boyin Hearing
|
Boyin Hearing offers a comprehensive selection of hearing treatments for persons suffering from hearing loss. | $13.7M / Series B / Jan 01, 2025 | |
| Le Ming Pharmaceuticals is a pharmaceutical enterprise focusing on R&D, production and sales of innovative pharmaceutical preparation. | $13.8M / Venture - Series Unknown / Jun 07, 2024 | ||
| Chenxi Health is a health technology company that focuses on medical insurance. | $13.8M / Series A / Apr 10, 2024 | ||
Ruishi Technology
|
Ruishi Technology develops Myopia prevention and control medical devices. | $14.2M / Series A / Aug 09, 2023 | |
|
Kejin Biotechnology
|
Kejin Biotechnology performs research and development of high-end laboratory consumables and membrane products for liquid treatment, molecular biology, cell preservation, and culture, which are based on innovative materials monopolized by imports. | $14.4M / May 11, 2023 | |
| Macrowing delivers data intelligent management and enterprise content management solutions to a variety of industries. Their solutions such as life sciences, energy, construction engineering, design industry, finance, real estate, government, and IT internet. Their content business such as content low code platforms, knowledge management, andsystem document management. | Seed / Mar 02, 2023 | ||
| 4iNLOOK was founded in 2008 and now has more than 300 specialty color contact lens stores nationwide, mainly in shopping centers in first-and second-tier cities. It offers more than 200 color contact lens options with different designs for women aged 18-30. Meanwhile, 4iNLOOK is also opening up online channels, with its Tmall store and nationalchain stores offering a new retail shopping experience that allows consumers to place orders online, take orders offline, make appointments online, and experience the products offline. | Venture - Series Unknown / Jan 10, 2023 | ||
|
Ruishi Technology
|
Ruishi Technology develops Myopia prevention and control medical devices. | $7.2M / Series A / Dec 15, 2022 | |
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sinopharm-CICC invest in?
Sinopharm-CICC invests primarily in Medical, Biotechnology and Health Care startups, most often at Series A and Venture - Series Unknown stage. Most of the 15 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Sinopharm-CICC last invest?
The most recent investment recorded for Sinopharm-CICC closed in Nov 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
